Opus Genetics IRD Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Opus Genetics’s reported figures.
Based on trailing twelve months.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's return on equity?
- Opus Genetics (IRD) reported return on equity of -449.4% in Q4 2025.
- How has Opus Genetics's return on equity changed year-over-year?
- Opus Genetics's return on equity decreased by 121.2% year-over-year, from -203.2% to -449.4%.
- What is the long-term trend for Opus Genetics's return on equity?
- Over 3 years (2022 to 2025), Opus Genetics's return on equity has grown at a 104.9% compound annual growth rate (CAGR), from 52.3% to -449.4%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.